Abstract | OBJECTIVE: METHODS: A total of 51 cases with advanced GIST were proved pathologically. Among them, CD117 was detected positive in 47 patients and negative in 4 patients; 4 patients received imatinib mesylate before operation and 47 patients with unresectable and (or) metastatic GIST received oral imatinib mesylate daily at dose of 300-800 mg. One patient was lost in follow-up and the objective effect was evaluated in 50 patients. RESULTS: 3 of the 50 patients (6.0%) achieved complete response (CR), 34 (68%) had partial response (PR), 5 (10.0%) had stable disease (SD) and 8 (20.0%) had progression disease (PD). The median time to progression ( mTTP) was 16 months during which most of the patients experienced benefit. 32 patients had been followed up for more then 1 year. The 1-year and 2-year survival rate were 95.3%, 89% respectively. 50 patients were valuable for the toxicity assessment according to the WHO standard. The main toxicity included grade I-II edema of periorbital area and lower limb in 72.0% (36/50) patients, leukopenia was present in 46% (23/50) and intratumoral bleeding in 4.0% (2/50). Other toxicities included mild fatigue (28.0%), abdominal pain (14.0%), efflorescence (18.0%), nausea and vomiting (18.0%). CONCLUSIONS:
|
Authors | De-sen Wan, Xiao-jun Wu, Zhi-zhong Pan, Zhi-wei Zhou, Gong Chen, Li-ren Li, Zhen-hai Lu, Pei-rong Ding |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 86
Issue 43
Pg. 3064-7
(Nov 21 2006)
ISSN: 0376-2491 [Print] China |
PMID | 17288838
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Benzamides
- Female
- Follow-Up Studies
- Gastrointestinal Neoplasms
(drug therapy, pathology)
- Gastrointestinal Stromal Tumors
(drug therapy, pathology)
- Humans
- Imatinib Mesylate
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Piperazines
(adverse effects, therapeutic use)
- Premedication
- Preoperative Care
- Pyrimidines
(adverse effects, therapeutic use)
- Retrospective Studies
|